Evaluation of potentiation of anti-PD-L1 treatment using in vitro models

• Authors: ČUDOVÁ Martina; MELICHAROVÁ Jana; KOLLÁR Peter; KAUEROVÁ Tereza
• Year of publication: 2025
• Type: Appeared in Conference without Proceedings
• MU Faculty or unit: Faculty of Pharmacy
• Description: Immunotherapy has become one of the most important approaches to cancer treatment. Inhibition of immune system checkpoints, specifically targeting programmed cell death protein and ligand (PD-1, PD-L1), is a key strategy in cancer immunotherapy. Anti-PD-L1 therapy, which blocks the interaction between PD-L1 on tumor cells and PD-1 on T-lymphocytes, can restore immune activity and promote tumor regression. Despite significant clinical success in several cancers, including non-small cell lung cancer, the therapeutic efficacy of anti-PD-L1 therapy remains limited in a subgroup of patients. Therefore, potential strategies to enhance therapeutic response are currently under investigation. Our study focuses on evaluating potentiation of anti-PD-L1 therapy using in vitro models. Namely, two types of co-culture models of activated T-lymphocytes, PD-L1-expressing tumor cell lines and anti-PD-L1 antitumor immunotherapy representative were developed. Their functionality was verified using salicylanilide derivatives. Our co-culture models are of great importance for the study of potentiation of antitumor immunotherapy in vitro.

Related projects

• Study of the effect of salicylanilide derivatives on PD-L1 expression in cancer cell lines
• Use of a co-culture model of activated T-lymphocytes with a human tumor cell line to evaluate the synergism of checkpoint inhibitors with selected drugs